Document is current
Any future updates will be listed below
-
Authors
Gruber, Ross C.
Wirak, Gregory S.
Blazier, Anna S.
Lee, Lan
Dufault, Michael R. https://orcid.org/0000-0002-5124-1627
Hagan, Nellwyn
Chretien, Nathalie
LaMorte, Michael
Hammond, Timothy R. https://orcid.org/0000-0001-7761-6362
Cheong, Agnes https://orcid.org/0000-0001-9424-0424
Ryan, Sean K.
Macklin, Andrew
Zhang, Mindy
Pande, Nilesh
Havari, Evis
Turner, Timothy J. https://orcid.org/0000-0001-9770-2647
Chomyk, Anthony https://orcid.org/0000-0002-6832-6221
Christie, Emilie https://orcid.org/0009-0005-2928-4697
Trapp, Bruce D. https://orcid.org/0000-0001-6682-3737
Ofengeim, Dimitry https://orcid.org/0000-0003-2348-3642
- License Information
-
More Information
Article History
Received: 22 May 2023
Accepted: 12 November 2024
First Online: 22 November 2024
Competing interests
: R.C.G., N.C., and N.P. were employees of Sanofi when this work was undertaken. G.S.W., A.S.B., L.L., M.R.D., N.H., M.L., T.R.H., A.Che, S.R., M.Z., E.H., A.M., T.J.T., and D.O. are employees of Sanofi and may hold shares and/or stock options in the company. ACho and EC declare that they have no competing interests. B.D.T has received consulting fees, speaker honoraria, and/or research funding from Biogen, Disarm Therapeutics, EMD Serono, Novartis, Renovo Neural, and Sanofi; and principal investigator and/or speaking fees from Alkermes, Biogen, Celgene, EMD Serono, Genentech/Roche, Novartis, Sanofi, and TG Therapeutics.
